Basic Info
  • Grade: pharmaceutical grade

    Factory Location: Shanghai

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Bugatinib is an oral inhibitor of receptor tyrosine kinase asexual lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), with potential anti-tumor activity. Bugatinib binds and inhibits ALK kinase and ALK fusion protein, as well as EGFR and mutants. This leads to inhibition of ALK kinase and EGFR kinase, disrupting their signaling pathways and ultimately inhibiting the growth of susceptible tumor cells. In addition, AP26113 seems to be able to overcome mutation based resistance. ALK belongs to the insulin receptor superfamily and plays an important role in the development of the nervous system; ALK dysregulation and gene rearrangement are associated with a range of tumors. EGFR is overexpressed in various types of cancer cells.
Send your message to this supplier
  • From:
  • To:
    Shanghai Hope-chem Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service